Tariff Impact Assessment

Despite a 10% tariff on shipments between European manufacturing sites and US distribution entities, Cook Medical management currently anticipates no significant direct impact on the entities’ business activities or their ability to continue operating.This assessment was made as of July 14th (year not specified,assumed 2025).

according to the report, sales prices from the European manufacturers have not yet been adjusted to reflect the tariffs. The US-based entities plan to pass the extra tariff costs onto customers “where possible,” supplemented by internal cost-saving initiatives to cover any remaining difference.

Financial Performance in 2024

The Cook Medical EMEA Group, with manufacturing plants in Limerick, Ireland, and Denmark, recorded a post-tax loss of €93.5 million in 2024. This loss was primarily attributed to a substantial €166 million tax charge related to a specific tax matter concerning Cook Denmark International Holdings ApS.

Despite the loss, the group experienced positive revenue growth, increasing by 6% from €798.49 million in 2023 to €849.63 million in 2024. Pre-tax profits also saw a significant increase,rising by 52% from €61.9 million to €94.57 million.

The company reduced its workforce from 2,278 to 2,191 employees, resulting in a decrease in staff costs from €194.63 million to €190 million.